Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Yosuke, Nishikawa, Shingo, Ninomiya, Hironori, Yoshida, Reiko, Takano, Natsuki, Oguri, Tomoyo, Kitazono, Satoru, Yanagitani, Noriko, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Ishikawa, Yuichi, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548921/
https://www.ncbi.nlm.nih.gov/pubmed/31092773
http://dx.doi.org/10.2169/internalmedicine.1673-18
_version_ 1783423899744075776
author Kawashima, Yosuke
Nishikawa, Shingo
Ninomiya, Hironori
Yoshida, Reiko
Takano, Natsuki
Oguri, Tomoyo
Kitazono, Satoru
Yanagitani, Noriko
Horiike, Atsushi
Ohyanagi, Fumiyoshi
Ishikawa, Yuichi
Nishio, Makoto
author_facet Kawashima, Yosuke
Nishikawa, Shingo
Ninomiya, Hironori
Yoshida, Reiko
Takano, Natsuki
Oguri, Tomoyo
Kitazono, Satoru
Yanagitani, Noriko
Horiike, Atsushi
Ohyanagi, Fumiyoshi
Ishikawa, Yuichi
Nishio, Makoto
author_sort Kawashima, Yosuke
collection PubMed
description Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab.
format Online
Article
Text
id pubmed-6548921
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-65489212019-06-17 Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab Kawashima, Yosuke Nishikawa, Shingo Ninomiya, Hironori Yoshida, Reiko Takano, Natsuki Oguri, Tomoyo Kitazono, Satoru Yanagitani, Noriko Horiike, Atsushi Ohyanagi, Fumiyoshi Ishikawa, Yuichi Nishio, Makoto Intern Med Case Report Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab. The Japanese Society of Internal Medicine 2019-05-15 /pmc/articles/PMC6548921/ /pubmed/31092773 http://dx.doi.org/10.2169/internalmedicine.1673-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kawashima, Yosuke
Nishikawa, Shingo
Ninomiya, Hironori
Yoshida, Reiko
Takano, Natsuki
Oguri, Tomoyo
Kitazono, Satoru
Yanagitani, Noriko
Horiike, Atsushi
Ohyanagi, Fumiyoshi
Ishikawa, Yuichi
Nishio, Makoto
Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title_full Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title_fullStr Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title_full_unstemmed Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title_short Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
title_sort lung adenocarcinoma with lynch syndrome and the response to nivolumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548921/
https://www.ncbi.nlm.nih.gov/pubmed/31092773
http://dx.doi.org/10.2169/internalmedicine.1673-18
work_keys_str_mv AT kawashimayosuke lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT nishikawashingo lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT ninomiyahironori lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT yoshidareiko lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT takanonatsuki lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT oguritomoyo lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT kitazonosatoru lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT yanagitaninoriko lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT horiikeatsushi lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT ohyanagifumiyoshi lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT ishikawayuichi lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab
AT nishiomakoto lungadenocarcinomawithlynchsyndromeandtheresponsetonivolumab

Ejemplares similares